- Home
- GLO vs EDIT Comparison
GLO vs EDIT Comparison
Compare GLO & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLO
- EDIT
- Stock Information
- Founded
- GLO 2006
- EDIT 2013
- Country
- GLO United States
- EDIT United States
- Employees
- GLO N/A
- EDIT N/A
- Industry
- GLO Finance/Investors Services
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLO Finance
- EDIT Health Care
- Exchange
- GLO Nasdaq
- EDIT Nasdaq
- Market Cap
- GLO 242.5M
- EDIT 241.9M
- IPO Year
- GLO N/A
- EDIT 2016
- Fundamental
- Price
- GLO $5.69
- EDIT $2.67
- Analyst Decision
- GLO
- EDIT Buy
- Analyst Count
- GLO 0
- EDIT 12
- Target Price
- GLO N/A
- EDIT $5.40
- AVG Volume (30 Days)
- GLO 170.5K
- EDIT 1.2M
- Earning Date
- GLO 01-01-0001
- EDIT 11-03-2025
- Dividend Yield
- GLO 11.38%
- EDIT N/A
- EPS Growth
- GLO N/A
- EDIT N/A
- EPS
- GLO N/A
- EDIT N/A
- Revenue
- GLO N/A
- EDIT $38,901,000.00
- Revenue This Year
- GLO N/A
- EDIT N/A
- Revenue Next Year
- GLO N/A
- EDIT N/A
- P/E Ratio
- GLO N/A
- EDIT N/A
- Revenue Growth
- GLO N/A
- EDIT N/A
- 52 Week Low
- GLO $4.08
- EDIT $0.91
- 52 Week High
- GLO $5.18
- EDIT $4.12
- Technical
- Relative Strength Index (RSI)
- GLO 67.95
- EDIT 50.32
- Support Level
- GLO $5.63
- EDIT $2.56
- Resistance Level
- GLO $5.60
- EDIT $2.84
- Average True Range (ATR)
- GLO 0.05
- EDIT 0.17
- MACD
- GLO 0.01
- EDIT 0.00
- Stochastic Oscillator
- GLO 86.99
- EDIT 62.22
About GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.